Transcept gains cash and public listing through Novacea merger
This article was originally published in Scrip
Executive Summary
Transcept Pharmaceuticals is to gain $84 million in cash and become a publicly listed company through a merger with Novacea. Transcept improves existing drugs or develops new indications for existing prescription sleep medicine and psychiatry drugs and its lead agent Intermezzo (zolpidem), for middle-of-the-night insomnia, has completed two Phase III trials.